Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Adams, Richard; Meade, Angela; Seymour, Michel; H. Wilson, Richard; Madi, Ayman; J. Fisher, David; Kenny, Sarah; Kay, Edward; Hodgkinson, Elizabeth; Pope, Malcolm; Rogers, P.; Wasan, Harpreet; Falk, Stephen; Gollins, Simon; Hickish, Tamas; Bessell, E.M.; Propper, David; Kennedy, Megan; Kaplan, Richard; Maughan, Tim

doi:10.1016/s1470-2045(11)70102-4

Public

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Published in The Lancet Oncology • Jun 12, 2011

Authors:

Richard Adams

Angela Meade

Michel Seymour

Abstract

BACKGROUND: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to ach...

Subject

Medicine

Oxaliplatin

Colorectal cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!